Phase 1

Image of a Petri dish and pipette with sample


CD40-CD40L interaction is an attractive target for blocking T-cell–mediated B-cell–driven autoimmunity and prevention of solid organ transplant rejection. External proof-of-concept for inhibition of this pathway has been previously established in patients with a broad range of autoimmune diseases, including rheumatoid arthritis, Sjögren’s syndrome, Graves’ disease, systemic lupus erythematosus and solid organ transplant.

Status: Phase 1

We are enrolling healthy subjects in a single-ascending-dose Phase 1 clinical trial. The first-in-human trial will provide safety data and pharmacokinetics as well as receptor occupancy and T-cell Dependent Antibody Responses. Data are expected in the fourth quarter of 2020.

Explore Our Pipeline

We are intent on developing an array of innovative therapies that answer the many and varied needs of patients.